Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting

被引：2
|
作者：
Ferrarazzo, Giulia [1 ,2 ]
Chiola, Silvia [3 ]
Capitanio, Selene [4 ]
Donegani, Maria Isabella [1 ,2 ]
Miceli, Alberto [1 ,2 ]
Raffa, Stefano [1 ,2 ]
Tagliafico, Alberto Stefano [1 ,5 ]
Morbelli, Silvia [1 ,2 ]
Bauckneht, Matteo [1 ,2 ]
机构：
[1] IRCCS Osped Policlin San Martino, I-16132 Genoa, Italy
[2] Univ Genoa, Dept Hlth Sci, Nucl Med Unit, I-16132 Genoa, Italy
[3] Humanitas Clin & Res Ctr IRCCS, Dept Nucl Med, I-20089 Milan, Italy
[4] ASST Grande Osped Metropolitano Niguarda, Dept Adv Diagnost Therapeut Technol, Nucl Med, I-20162 Milan, Italy
[5] Univ Genoa, Dept Hlth Sci, Radiol Unit, I-16132 Genoa, Italy
来源：
DIAGNOSTICS | 2021年 / 11卷 / 02期
关键词：
multiple myeloma; positron emission tomography; magnetic resonance imaging; response assessment; CONTRAST-ENHANCED MRI; WHOLE-BODY MRI; F-18-FDG PET/CT; FDG PET/CT; COMPUTED-TOMOGRAPHY; INTERPRETATION CRITERIA; RESPONSE EVALUATION; FOLLOW-UP; PREDICTION; THERAPY;
D O I：
10.3390/diagnostics11020230
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (FDG PET/CT) has an established clinical value in the diagnosis and initial staging of multiple myeloma (MM). In the last ten years, a vast body of literature has shown that this tool can also be of high relevance for monitoring therapy responses, making it the recommended imaging approach in this field. Starting from the strengths and weaknesses of radiological imaging in MM, the present review aims to analyze FDG PET/CT's current clinical value focusing on therapy response assessment and objective interpretation criteria for therapy monitoring. Given the potential occurrence of patients with MM showing non-FDG-avid bone disease, new opportunities can be provided by non-FDG PET tracers. Accordingly, the potential role of non-FDG PET tracers in this setting has also been discussed.
引用
收藏
页数：18
相关论文
共 50 条
  • [21] [18F]Florbetaben positron emission tomography for imaging amyloidosis in multiple myeloma patients
    Seo, Minjung
    Cha, Hee Jeong
    Park, Sang Hyuk
    Jo, Jae Cheol
    Park, Seol Hoon
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [22] Positron Emission Tomography for oncologic imaging and treatment
    Bourland, JD
    MEDICAL PHYSICS, 2005, 32 (06) : 2119 - 2120
  • [23] Positron emission tomography for oncologic imaging and treatment
    Bourland, J.
    MEDICAL PHYSICS, 2006, 33 (06) : 2178 - 2179
  • [24] ACCURACY OF PROTON BEAM RANGE VERIFICATION USING POST-TREATMENT POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY AS FUNCTION OF TREATMENT SITE
    Knopf, Antje-Christin
    Parodi, Katia
    Paganetti, Harald
    Bortfeld, Thomas
    Daartz, Juliane
    Engelsman, Martijn
    Liebsch, Norbert
    Shih, Helen
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (01): : 297 - 304
  • [25] Fluoro-deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma
    Orchard, K
    Barrington, S
    Buscombe, J
    Hilson, A
    Prentice, HG
    Mehta, A
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (01) : 133 - 135
  • [26] Positron emission tomography: PET
    Sugano, Yuichi
    Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry, 1996, 54 (05): : 401 - 409
  • [27] Positron emission tomography: PET
    Sugano, Y
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 1996, 54 (05) : 401 - 409
  • [28] Positron Emission Tomography (PET)
    Oltmanns, Doerte
    CHEMIE IN UNSERER ZEIT, 2015, 49 (01) : 7 - 7
  • [29] POSITRON EMISSION TOMOGRAPHY (PET)
    TERPOGOSSIAN, MM
    RADIATION RESEARCH, 1982, 91 (02) : 278 - 278
  • [30] Positron emission tomography (PET) and myocardial perfusion imaging (MPI)
    Simon, E
    Machac, J
    ETHNICITY & DISEASE, 2005, 15 (03) : 103 - 104
12345